ESMO 2016 Abstract 941TiP - Pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM): Randomized, phase 3 KEYNOTE-183 study

The randomized, open-label, phase 3 KEYNOTE-183 study (, NCT02576977) was designed to compare the efficacy of pomalidomide and low-dose dexamethasone with or without pembrolizumab in patients with rrMM.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.